Technology Bundle ID

Method of Enhancing Opsonophagocytosis

Linked ID
Edwin Ades (CDC)
George Carlone (CDC)
GowriSankar Rajam (CDC)
Jacquelyn Sampson (CDC)
Joseph Caba (CDC)
Joseph Martinez (CDC)
Nikkol Atwell-Melnick
Melnick (CDC)
Sandra Steiner (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading to prolonged survival. This technology enhances the body's response to infections such as S. pneumoniae and S. aureus.
Commercial Applications
  • Opsonic therapy
  • Passive immunization
  • Enhancement of pathogen clearing
  • Synergistic use with other therapies
Competitive Advantages
  • Multiple in vivo studies indicate significant improvements in recipient outcomes
  • Highly adaptable and can be combined with a number of alternate therapies
  • Enhances opsonophagoctyosis to achieve therapeutically effective results

Request More Info

Licensing Contact: